These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 25398229)

  • 1. Relapses and disability accumulation in progressive multiple sclerosis.
    Paz Soldán MM; Novotna M; Abou Zeid N; Kale N; Tutuncu M; Crusan DJ; Atkinson EJ; Siva A; Keegan BM; Pirko I; Pittock SJ; Lucchinetti CF; Weinshenker BG; Rodriguez M; Kantarci OH
    Neurology; 2015 Jan; 84(1):81-8. PubMed ID: 25398229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
    Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T;
    JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.
    Ribbons KA; McElduff P; Boz C; Trojano M; Izquierdo G; Duquette P; Girard M; Grand'Maison F; Hupperts R; Grammond P; Oreja-Guevara C; Petersen T; Bergamaschi R; Giuliani G; Barnett M; van Pesch V; Amato MP; Iuliano G; Fiol M; Slee M; Verheul F; Cristiano E; Fernandez-Bolanos R; Saladino ML; Rio ME; Cabrera-Gomez J; Butzkueven H; van Munster E; Den Braber-Moerland L; La Spitaleri D; Lugaresi A; Shaygannejad V; Gray O; Deri N; Alroughani R; Lechner-Scott J
    PLoS One; 2015; 10(6):e0122686. PubMed ID: 26046348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis.
    D'hooghe MB; Haentjens P; Nagels G; Garmyn M; De Keyser J
    Mult Scler; 2012 Apr; 18(4):451-9. PubMed ID: 21952096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The natural history of early versus late disability accumulation in primary progressive MS.
    Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
    Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
    JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
    Sayao AL; Devonshire V; Tremlett H
    Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of multiple sclerosis relapses on progression diminishes with time.
    Tremlett H; Yousefi M; Devonshire V; Rieckmann P; Zhao Y;
    Neurology; 2009 Nov; 73(20):1616-23. PubMed ID: 19890070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term disability progression of pediatric-onset multiple sclerosis.
    McKay KA; Hillert J; Manouchehrinia A
    Neurology; 2019 Jun; 92(24):e2764-e2773. PubMed ID: 31092624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
    Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of clinical characteristics for 'benign' multiple sclerosis.
    Ramsaransing GS; De Keyser J
    Eur J Neurol; 2007 Aug; 14(8):885-9. PubMed ID: 17662009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
    Debouverie M; Vandenberghe N; Morrissey SP; Anxionnat R; Pittion-Vouyovitch S; Vespignani H; Edan G
    Mult Scler; 2004 Aug; 10(4):407-12. PubMed ID: 15327038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
    Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
    Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-beta and disability progression in relapsing-remitting multiple sclerosis.
    Drulovic J; Kostic J; Mesaros S; Dujmovic Basuroski I; Stojsavljevic N; Kisic-Tepavcevic D; Pekmezovic T
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S65-9. PubMed ID: 24321159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.